Drug Trial Radar · NCT04170595
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Last checked: Nov 19, 2026Latest source record: Mar 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
132
Planned (sponsor's estimate)
Start
Mar 28, 2014
Primary completion
Dec 2021
Study completion Dec 2022
Sponsor
- Lead sponsor
- Genor Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, multicenter, Phase I/IIa clinical study to evaluate the tolerability, safety, efficacy, pharmacokinetics and immunogenicity after single/multiple administration of recombinant anti-HER2 humanized monoclonal antibody for injection for the treatment of HER2-positive breast cancer patients.
Conditions
- HER2-positive Breast Cancer
Interventions
GB221,2 mg/kgBiological
Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
GB221,6 mg/kgBiological
Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
Herceptin,6 mg/kgBiological
Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
GB221,8mg/kgBiological
Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
GB221:2mg/kg and Capecitabi:1000mg/kgBiological
GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
Herceptin:2mg/kg and Capecitabin:1000mg/kgBiological
Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- maximum tolerated dose,MTDTime frame: Up to 5 weeks
- C maxTime frame: Up to 5 weeks
- AUC (0- t)Time frame: Up to 5 weeks
- AUC (0- ∞ )Time frame: Up to 5 weeks
- T maxTime frame: Up to 5 weeks
- T 1/2Time frame: Up to 5 weeks
- CL/FTime frame: Up to 5 weeks
- V/FTime frame: Up to 5 weeks
- K eTime frame: Up to 5 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Academy of Military Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.